- InnovAge Holding reported first quarter 2027 results for the period ended September 30, 2026, with revenue of US$264.76 million and net income of US$19.55 million, alongside basic and diluted EPS from continuing operations of US$0.14 compared with US$0.06 a year earlier.
- The company paired this stronger earnings profile with confirmed fiscal 2027 guidance for total revenue of US$1.05b to US$1.085b, which directly relates to execution against its PACE model and cost control priorities highlighted in earlier analyses.
- We will now look at how InnovAge Holding's higher quarterly earnings may influence the existing investment narrative around PACE-driven growth.
Scan how InnovAge Holding's latest guidance compares with peers by moving through a curated set of 32 high quality undervalued stocks that combine earnings power with balance sheet strength.
InnovAge Holding Investment Narrative Recap
For an investor in InnovAge Holding, the core belief is that the PACE model can support steady enrollment, tight medical cost control, and eventually meaningfully higher profitability. The latest quarter shows revenue of US$264.76 million, net income of US$19.55 million, and EPS of US$0.14, which points to an operating setup that currently supports positive earnings.
The analyst consensus Narrative on Simply Wall St leans heavily on cost discipline and execution against PACE as the key near term catalyst. The confirmed fiscal 2027 revenue guidance of US$1.05b to US$1.085b keeps that thesis intact. The biggest near term risk remains any loss of control over external provider, salary, or pharmacy costs.
The most relevant announcement for this update is the reaffirmed fiscal 2027 revenue outlook of US$1.05b to US$1.085b. That range links directly to InnovAge Holding’s efforts to fill existing centers, support enrollment, and keep the integrated care model functioning efficiently at scale.
This same guidance is also a clear reference point for the catalysts highlighted in earlier commentary, including operational transformation and pharmacy integration. Any meaningful miss versus that revenue band, whether from softer census trends or higher care delivery expenses, would test the idea that margins and earnings can build from here in a consistent way.
Analysts expect InnovAge Holding's narrative to converge on revenues of US$1.3b and earnings of US$181.3 million by 2029, based on projected 7.5% yearly revenue growth and an earnings increase of about US$172.3 million from US$9.0 million today.
Uncover why InnovAge Holding's fair value indicates a 26% potential upside to its current price that may not last much longer.
Exploring Other Perspectives
One alternate view highlights acquisition led expansion as the real swing factor for InnovAge Holding. The most optimistic analysts were already framing 8.6% yearly revenue growth and earnings of about US$158.4 million by 2029, built around faster deals and integrations. Those expectations were set before this quarter’s results, so you may see those narratives shift as fresh data filters through.
Explore another InnovAge Holding fair value estimate, including one that suggests as much as 351% potential increase from the current price.
Decide For Yourself
Disagree with existing narratives? Extraordinary investment outcomes rarely come from following the herd, so consider your own analysis carefully.
- A great starting point for your InnovAge Holding research is our analysis highlighting 3 key rewards that could impact your investment decision.
- See our latest analysis for InnovAge Holding. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate InnovAge Holding's overall financial health at a glance.
Looking for more InnovAge Holding sized ideas?
If InnovAge Holding has sharpened your view on what you want in a business, you can use the Simply Wall St Screener to hunt for other stocks that fit your checklist on quality, resilience, or income potential.
- For investors who care most about valuation discipline and underlying financial strength, scan a curated 32 high quality undervalued stocks that line up solid cash generation with balance sheet support.
- If capital preservation and a smoother ride matter more to you than chasing every rally, filter the market using a 30 resilient stocks with low risk scores that focuses on resilient fundamentals and lower risk scores.
- When you want to get ahead of the crowd and focus on potential future leaders rather than the usual large caps, comb through a 19 high quality undiscovered gems built around strong financial quality that has not yet attracted wide attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com